BCI Pharma and Mithra will start a collaboration to deliver new therapy for women! Mithra acquires the rights relating to BCI development program on innovative inhibitors of CSF1R kinase indicated for the treatment of female cancers and endometriosis. Press release

GSO congrès

BCI Pharma will present its promising research program targeting tumor-associated macrophages. Mode of action and efficacy data of its preclinical candidate will be discussed.